Search Results

COMPLETE SCAM WATCHING REPORT Company Details: Oros Research Entity:  OROS Research / OROS, Inc. Website :   https://orosresearch.com BBB Officers Listed: Zack Joseph , Vice President / Co-Founder Tommy Guess , President / Co-Founder Claimed Address:  105 Brady Ct. #B, Cary, NC 27511 Phone:  +1 (910) 250-8786 Claimed Manufacturing Facility: “Formulated in our California-based partner facility under strict GMP-compliant conditions.” Legal Entity Listed in Terms:  OROS, Inc. Business Start Date (According to BBB):  March 12, 2025 Incorporation Date:  March 12, 2025 Alternate Names / DBA:  “OROS, Inc.” Employed (LinkedIn): 2-10 listed Social Media:   Facebook page : titled “OROS Research” https://www.facebook.com/orosresearch Instagram: @ orosresearch https://www.instagram.com/orosresearch X: @ orosresearch https://x.com/orosresearch Scam Score A 1-star rating represents the lowest tier in our trust scale and signals high probability of deception, non-compliance, or consumer harm. Vendors in this category exhibit one or more of the following: Verified false or misleading claims about origin, purity, or manufacturing. Unverifiable lab documents (missing accreditation, self-issued, or forged). Violations of federal or platform policies (FDA, FTC, Shopify, Stripe, etc.). Mismatch between corporate filings, claimed experience, and public data. Evidence of dosing/reconstitution instructions implying human use despite “research only” disclaimers. Impact: This low of a trust score automatically places the entity on ScamWatching.org  red-flag status  🚩— meaning the brand is considered untrustworthy until independently verified . Listings under this score are recommended for public exposure, platform reporting, and community alerting . OROS RESEARCH GENERAL OVERIVIEW Oros Research presents itself as a U.S.-based manufacturer of “high-purity, California-made” research peptides through its website at https://orosresearch.com . According to the Better Business Bureau listing for the company ( https://www.bbb.org/us/nc/cary/profile/biotechnology/oros-research-0593-90366833 ), Oros Research was incorporated on March 12, 2025 , making it an extremely new operation despite its polished pharmaceutical-style branding. Domain registration records from ScamAdviser  ( https://www.scamadviser.com/check-website/orosresearch.com ) show that the site itself was registered just weeks before incorporation, raising immediate concerns about how a newly formed business can claim established GMP facilities and DEA-licensed laboratory partnerships. SUMMARY ASSESSMENT Oros Research operates through its website, https://orosresearch.com , and lists its corporate identity as OROS, Inc. According to the Better Business Bureau, the company was founded and incorporated on March 12, 2025, making it a very new entrant into the peptide market. The BBB listing identifies two individuals as company officers: Zack Joseph, serving as Vice President and Co-Founder, and Tommy Guess, listed as President and Co-Founder. Oros Research claims to be headquartered at 105 Brady Ct. #B, Cary, North Carolina, which serves as its primary business address. The company provides a single contact number, +1 (910) 250-8786, and maintains a social media presence through a Facebook page under the name “Oros Research.” On its website, Oros Research describes itself as a distributor of research-use-only (RUO) peptides, emphasizing that its products are “not intended for human or animal consumption.” However, despite this RUO positioning, the company markets its peptides with pharmaceutical-style branding, complete with lot numbers, endotoxin testing claims, and references to sterile formulation environments. What Oros Research Claims Across its website, Oros Research repeatedly asserts that its peptides are “California-Made” and manufactured in a “California-based partner facility under strict GMP and ISO-compliant conditions.”  These statements appear prominently on the homepage ( https://orosresearch.com ) and again in the company FAQ ( https://orosresearch.com/pages/faq ). The legal disclaimers reinforce that all products are tested at “DEA-licensed, U.S.-based laboratories.” However, no page on the site provides a facility name, address, license number, GMP certificate, ISO credential, or DEA laboratory identifier. The company continues to operate exclusively from its North Carolina address, with no public record of a corresponding California manufacturing plant in the California Secretary of State business registry  ( https://bizfileonline.sos.ca.gov/search/business ). If Oros Research truly manufactures its peptides in California, why is the only verifiable business address located in North Carolina , with no evidence of any California facility? Even the laboratory they claim performs their COA testing is not based in California, further undermining their manufacturing claims . This photo shows the business address listed on Oros Research’s own website. As the screenshot confirms, there is no indication of any California-based manufacturing facility at this location, further undermining their claim of operating a “California lab.” VIOLATIONS AND RED FLAGS Discrepancies in Manufacturing Claims Although the company makes repeated claims about California manufacturing, no public filing exists for OROS, Inc.  or Oros Research  in the state of California — and no manufacturing site is disclosed anywhere on the website. The only verified physical location remains the Cary, North Carolina office listed on both the Contact Page  and the BBB record . This mismatch between claimed and verifiable facility locations is significant. Given that Oros Research was incorporated on March 12, 2025 (BBB), and its website registered on February 18, 2025 (ScamAdviser), it is unlikely that the company established a fully compliant GMP manufacturing plant in California during this timeframe. No FDA manufacturing registration or outsourcing facility listing exists for Oros Research in the FDA 503B Outsourcing Facility Database  ( https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities ). Product Presentation That Mirrors Consumer-Use Peptide Vendors Despite labeling its products as RUO, Oros Research markets sterile peptide vials in exact consumer-ready dosing formats, including 5mg, 10mg, and 15mg sterile lyophilized powders. Examples include Retatrutide  ( https://orosresearch.com/products/retatrutide-peptide ), Melanotan-II  ( https://orosresearch.com/products/melanotan-2 ),and GHK-Cu/BPC-157/TB-500 “Glow Blend”  ( https://orosresearch.com/products/ghk-cu-bpc157-tb500 ). They also sell BPC-157 capsules  ( https://orosresearch.com/products/bpc-157-capsules ), a dosage form intended for oral consumption — not laboratory research. FDA has publicly warned against peptide suppliers using RUO language to disguise products clearly intended for human use. See FDA’s RUO Guidance ( https://www.fda.gov/regulatory-information/search-fda-guidance-documents/research-use-only-ruo-labeling-medical-devices ) and FDA’s consumer update on unapproved peptides ( https://www.fda.gov/consumers/consumer-updates/avoid-unapproved-hormones-and-peptides ). These warnings directly apply to the types of products Oros Research is selling. Inconsistent Use of Regulatory Terminology Oros Research states that RUO products are “not subject to serialization requirements” (Terms & Conditions), yet the company simultaneously displays lot numbers  and purity percentages  on product pages, creating conflicting messaging. Claims of “GMP” and “ISO 5 Laminar Flow Facility” appear in multiple sections of the site, but unlike legitimate manufacturers, the company provides no facility certification numbers , no ISO reports , no audit documentation , and no GMP site listing . FDA guidance on misbranding ( https://www.fda.gov/industry/fda-basics-industry/drug-misbranding ) highlights that using regulatory language without lawful compliance is considered misleading — another area where Oros Research’s claims appear problematic. The COA Lab: Freedom Diagnostics Testing Oros Research states that its COAs come from “DEA-licensed” labs, but multiple product pages and support notes reference Freedom Diagnostics Testing , whose website is https://freedomdiagnosticstesting.com . Freedom Diagnostics Testing lists an address at 133 Holiday Ct Suite 106, Franklin, TN 37067   This same suite, however, is used by multiple unrelated businesses, including Farmers Insurance – Kevin Clingan  ( https://agents.farmers.com/tn/franklin/kevin-clingan ) and Employee Prosperity Partners  . There is no indication  that a licensed analytical laboratory operates at this location. The Freedom Diagnostics blog shows only a default “Hello world!” post dated February 14, 2025 , confirming the site was created just days before Oros Research’s own domain registration. Domain verification (ScamAdviser) for Freedom Diagnostics also confirms February 2025 creation: https://www.scamadviser.com/check-website/freedomdiagnosticstesting.com Critically, no CLIA license , ISO 17025 accreditation , state lab license , or DEA analytical lab listing  exists for Freedom Diagnostics Testing in the NPI Registry  ( https://npiregistry.cms.hhs.gov/search ) or the DEA analytical laboratory directory  ( https://www.deadiversion.usdoj.gov ). This suggests the lab may not exist as a legitimate analytical facility and may instead be a companion entity created to give Oros Research the appearance of third-party testing. A Reddit discussion on peptide testing labs ( https://www.reddit.com/r/massspectrometry/comments/14fjda1/need_recommendation_on_who_can_test_peptides_for/ ) also raises concerns about suspicious and unverifiable labs being used by emerging peptide vendors. To back up on U/dDhyana response, we believe we have found some of Freedom Diagnostics "shill" accounts created to advertise them on reddit. Coordinated Website Creation Timeline A striking detail in this investigation is the timing of the domain registrations. OROS Research ( orosresearch.com ) was registered on February 18, 2025, and the testing lab they claim to use, Freedom Diagnostics Testing ( freedomdiagnosticstesting.com ), was registered just four days earlier on February 14, 2025. The close timing suggests both entities emerged simultaneously, raising serious questions about whether the “independent third-party testing lab” existed before OROS Research needed it. Rather than two established companies partnering, the evidence points toward two newly created websites built in parallel — a pattern that often appears in manufactured legitimacy or self-issued COA ecosystems. FDA Crackdown: Three Peptide Companies Cited for the Same Violations Seen at Alpha BioMed These are not isolated cases.  Recent FDA warning letters to GLP-1 Solution, ASN-LABS, and SemaSpace all describe the same core violations: online vendors selling Semaglutide, Tirzepatide, Retatrutide and related GLP-1 drugs directly to consumers as “research” or “compounded” products, without approval and with misleading marketing. U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2   Oros Research’s catalog of GLP-1-style peptides, cosmetic “blend” formulations, and research-only disclaimers places it squarely inside this enforcement pattern, even if it has not (yet) appeared on the FDA’s warning-letter list. Here are the top 3 companies that has been cited for the same violations seen at Oros Research GLP-1 Solution ( glp1solution.store ) WARNING LETTER (Sept 9, 2025) Direct link to warning letter: U.S Food & Drug Administration Despite claiming to offer “compounded” GLP-1 products, the company marketed retatrutide, semaglutide, and tirzepatide  as consumer-ready drugs. FDA determined they were unapproved new drugs  and misbranded , violating 505(a), 502(f)(1), 301(a), and 301(d) of the FD&C Act. ASN-LABS (asn-labs.com) WARNING LETTER (Sept 9, 2025) Direct link to warning letter: U.S Food & Drug Administration FDA found the company was offering retatrutide  and semaglutide  online as drug alternatives despite lacking approvals. Products were ruled unapproved new drugs  and misbranded , with marketing suggesting clinical/weight-loss use under the guise of “research chemicals.” SemaSpace ( www.semaspace.com ) WARNING LETTER 665848 (Oct 2, 2023) Direct link to warning letter: U.S Food & Drug Administration FDA determined SemaSpace was selling semaglutide injections  directly to consumers. The company’s marketing implied human therapeutic use, despite no drug approval or FDA oversight. Violations included unapproved new drugs , misbranding , and unsafe interstate distribution. GLP-1 Solution Warning Letter Highlighting Their Violations: ASN-LABS Warning Letter Highlighting Their Violations: SemaSpace Warning Letter Highlighting Their Violations: Public records, government databases, and the company’s own website collectively contradict Oros Research’s claims of California GMP manufacturing, DEA-licensed laboratory testing, and long-standing industry presence. The company appears to be a newly formed entity operating from a North Carolina office, selling peptides associated with human use despite RUO labeling, and relying on a testing lab that lacks recognizable licensing or laboratory credentials. Both Oros Research and Freedom Diagnostics Testing show signs of being formed simultaneously, lacking transparency, and lacking the infrastructure expected of compliant peptide manufacturers and testing labs. These findings suggest consumers and researchers should exercise extreme caution and verify all claims independently before engaging with this vendor. All findings and supporting evidence referenced in this report are sourced from publicly available records. Any attempt to alter or remove such material may constitute interference with public documentation and will be noted for compliance review. ______________________________________________________________________________________ Individuals who have experienced deceptive or unauthorized practices involving Alpha BioMed Labs are encouraged to file a report using our intake form for review and documentation. Submissions may be evaluated for potential escalation to a coordinated consumer complaint or class action proceeding if sufficient evidence is established.

COMPLETE SCAM WATCHING REPORT Company Details: Alpha Biomed Entity : Alpha BioMed Labs / Alpha BioMed Industries LLC Website :   https://alphabiomedlabs.com Parent LLC : Alpha Biomed LLC (Registered California Aug 27 2024) Entity #202463613310 Registered Agent:  Kaveh Newmen, 2107 N Broadway Suite 104, Santa Ana, CA 92706 Principal Address : 200 Spectrum Center Dr., Irvine, CA 92618 Phone:  (888) 890-8143 CEO / Owner:  Trevor Kruder (LinkedIn lists CEO of Alpha BioMed Industries, Paramount Peptides, Alpha BioMed Labs) Trademark Applications:  ALPHA BIOMED (Serial Nos. 98762857 & 98762885) — filed Sept 2024 under Alpha BioMed Industries LLC Employees (LinkedIn):  11 – 50 liste d Social Media: Facebook: Alpha BioMed Labs ( https://www.facebook.com/AlphaBioMedLabs/ ) Instagram: alphabiomedlabs ( https://www.instagram.com/alphabiomedlabs/ ) YouTube: @AlphaBioMed ( https://www.youtube.com/@AlphaBioMed ) TikTok: alphabiomedlabs ( https://www.tiktok.com/@alphabiomedlabs ) Scam Score A 1-star rating represents the lowest tier in our trust scale and signals high probability of deception, non-compliance, or consumer harm. Vendors in this category exhibit one or more of the following: Verified false or misleading claims about origin, purity, or manufacturing. Unverifiable lab documents (missing accreditation, self-issued, or forged). Violations of federal or platform policies (FDA, FTC, Shopify, Stripe, etc.). Mismatch between corporate filings, claimed experience, and public data. Evidence of dosing/reconstitution instructions implying human use despite “research only” disclaimers. Impact: This low of a trust score automatically places the entity on ScamWatching.org red-flag status 🚩— meaning the brand is considered untrustworthy until independently verified . Listings under this score are recommended for public exposure, platform reporting, and community alerting . ALPHA BIOMED PEPTIDES GENERAL OVERVIEW Alpha BioMed Labs presents itself as a “USA-based manufacturer and supplier of 99%+ pure peptides.” They emphasize “laboratories in the USA,” yet no public GMP registration or FDA establishment data exists . A “Greenville, SC campus” is mentioned for R&D and sterile vialing, but no address or license is publicly verifiable . They explicitly state they are not a 503A or 503B pharmacy, placing them in the “research use only” category while making therapeutic claims on SKU pages. SUMMARY ASSESSMENT Alpha BioMed Labs is a recently formed Shopify-hosted vendor posing as a long-standing U.S. manufacturer. Its public materials contain dosing and therapeutic language that violates both FDA advertising standards and Shopify/Stripe policy. COAs are provided by a notorious Chinese supporting testing lab and the Vials are clear like Chinese venders. Operational addresses in Irvine and Greenville appear front-office only. The evidence points to an American front built on a Chinese supply chain. There is nothing USA about this company other than it's branding. Primary risk vectors: regulatory exposure, payment processor lockout, and platform suspension. This makes them high-vulnerability for public audit and reporting campaigns. Platform Violation : Shopify AUP prohibits prescription drugs and research chemicals. Use of Shopify Payments (Stripe) compounds risk. Regulatory Risk:  Not FDA registered for manufacturing or repackaging drugs. Claims of “99% purity” and therapeutic effects qualify as drug claims under FDA/FTC guidelines. Timeline Inconsistency : LLC formed Aug 2024 but claims “over ten years of experience. Misleading Origins:  “USA labs” claim vs. unverified Greenville and Irvine locations creates potential false advertising exposure. PRODUCTS AND CLAIMS Offerings:  Full range of peptides (BPC-157, TB-500, GLP-1s, Selank, Semax, Tesamorelin, GHRP, Ipamorelin, HCG, etc.). Claim language:  Therapeutic statements appear on each page (“accelerates healing,” “enhances memory,” “improves metabolism”). Dosing Guides : Public “Dosing Guide” page exists; providers’ portal lists “Dosing Calculators.” A clinic-linked PDF titled “Peptide Ratios and Mixdowns – Alpha BioMed” contains mg/mL conversion tables and subQ/IM mix instructions — clear evidence of human-use guidance. Reconstitution Info:  Indirectly present in the mix-ratio guide. Purity Claims:  All SKUs advertise ≥ 99% purity from foreign testing that China uses. DIGITAL FOOTPRINT Platform:  Shopify (Refresh theme v15.x, Shopify Payments likely active). Hosting:  Shopify servers behind Cloudflare CDN. Checkout: Shopify standard cart and tax language detected (“Shopify does not allow tax refunds”). Payment Risk : Shopify and Stripe both ban peptides and research chemicals in their AUPs — their merchant account is at imminent risk of suspension. Domains/Subdomains:   providers.alphabiomedlabs.com | partners.alphabiomedlabs.com | alphabiomedlabs.com . VIOLATIONS AND RED FLAGS They repeatedly invoke “our laboratories” and “USA manufactured peptides,” but provide no FDA registration numbers, no GMP/ISO-17025 certificates, and no facility addresses. FDA’s device/lab database doesn’t show an obvious match for an “Alpha BioMed” at that Irvine address. That absence plus the anonymous “1M+ vials” claim is a red-flag combo.  Alpha BioMed Dosing and Medical Claims: A public PDF titled “Dosing Guide — Alpha BioMed” lives offsite and literally references their dosing page URL and Irvine address/phone. It includes titration schedules and unit conversions for Semaglutide and other peptides, e.g. “TITRATE UP FROM 250 MCG TO 2.5 MG, 1x per week,” and on PT-141 “AS NEEDED (2 hours before sexual activity).” That’s drug labeling. Not “research only.” Drug. Source:  Dosing Guide-Alpha Biomed Why that’s a legal problem: FDA has been slapping peptide sellers precisely for this: claims and dosing reveal intended use as human drugs, rendering them unapproved new drugs and misbranded. See FDA warning letters against peptide vendors for GLP-1 analogs and others; the pattern is identical.  U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2 Their BPC-157 (10mg) page claims “accelerate the healing of muscles, tendons, ligaments… GI tract,” “reduce inflammation,” “protecting the gut lining… IBD.” Those are disease and structure/function claims for a substance with no FDA approval . Source:  Alpha BioMed BPC-157 is not FDA-approved ; FDA lists it as a risky Category 2 bulk substance for compounding, and federal and sports bodies flag it as an unapproved drug. Selling it with ther apeutic claims is classic “unapproved and misbranded drug” territory.  GLP-1 claims: Their site banners push GLP-1s; FDA has recently issued waves of letters to peptide sites selling unapproved Semaglutide/Tirzepatide online. Again: same pattern, same violations. Source:  Alpha BioMed Company filings tying Alpha Biomed LLC/Industries to the Irvine address on the dosing document and site. Source:  Bizprofile Alpha Biomed Peptides has no GMP certs, no FDA registration posted despite “state-of-the-art laboratories” claims.  Alpha BioMed COA found with discrepancies: On the product page of Thymosin Beta 4 (TB500) 10 mg (10 mg vial) on the “Alpha BioMed” site, the description nominally says “Thymosin Beta 4 (TB500) (10mg) …” and markets wound healing, inflammation reduction, sports recovery.  Alpha BioMed In the screenshot  provided below (and linked visuals), there’s a Test Report (“Janos­hik Test Report”) image listing Sample: “TB4/BPC-157 Blend” with Batch BPC10N061125 (or similar) and specification lines showing BPC-157 ~11 mg and TB-500 ~10 mg. So it says “TB4/BPC-157 Blend” but the product label said “BPC-157 / TB500” (or maybe “TB-500/BPC-157”). That mismatch “TB4 vs TB500” is notable. From credible research sources: TB-500 is a synthetic analog  of full length TB4 (thymosin beta-4).   Peptide Sciences They are different peptides (different lengths, activity, regulatory status). For example, TB4 is full peptide of ~43 amino acids; TB-500 is a fragment (~7 amino acids) derived to mimic TB4.   Peptide Sciences This clearly shows that Alpha Biomed Peptides does not know the difference and do not understand the Peptides that they are selling. Also, the dosages are typically different for the fragment vs. the full chain. If COA doesn’t match product label, then what exactly was shipped? Mislabeling  or inconsistent naming  between product label and test report suggests either sloppy manufacturing/documentation or intentional obfuscation. Either way: risk. For regulatory enforcement: If a company sells “TB-500” but the COA/test says “TB4” (or vice versa), then the product is not accurately described. That can trigger misbranding issues under the FD&C Act (a drug must be labeled and tested as described). For consumer safety : They imply the compound is a known entity (“TB-500”) but their test certificate references a different molecule (“TB4”), which undermines traceability, testing validity, consistency of what the buyer gets. This mismatch is a piece of the narrative that the site is not manufacturing with full control or transparency, raising further red flags around sterile manufacturing claims, COA authenticity, etc. They sell bacteriostatic “Reconstitution Solution” explicitly “for injection,” beside peptide SKUs. “sterile… safe for injection… ideal for reconstituting peptides that require multiple doses… administration of peptides like GHRPs.” This pairs their powders with an injectable solvent and use-case. It screams intended human use.  Alpha BioMed FDA’s warnings on unapproved GLP-1 sellers note that instructions and materials enabling dosing evidence intended use as drugs.  U.S. Food and Drug Administration Social accounts look fake/dead Footer links to Facebook/Instagram/TikTok/YouTube are present, but the Facebook and Instagram endpoints don’t resolve in a normal way and appear abandoned or removed, which matches the screenshots of a dead FB page and a removed IG account. The broken links are visible across the site footer.  Alpha BioMed Since their social accounts on their main website were banned, they created a new account in October 2025 and pumped it with fake Instagram accounts to make it look real. Alpha Biomed Peptides first post after their original Instagram has been banned:   Alpha BioMed’s deceptive professional framing and structural compliance flaw . On their website for providers multiple blocks show duplicative widgets and “Best Sellers” repeats rather than organic reviews. I didn’t find verifiable review provenance or unique per-SKU review counts. The site structure screams prefab theme with placeholders swapped in late. Source:  Alpha BioMed Lets breakdown their "Provider's Intake Form" Regulatory Misrepresentation They market “provider-only” access, which implies DEA, FDA, or at least state-level verification of medical credentials. But their intake form lets anyone bypass those checkpoints by clicking “Not sure.”  That means they’re pretending to operate in a restricted-access model without enforcing it. Angle:  It’s a textbook example of false gatekeeping  — giving the illusion of regulation to look legitimate while quietly opening the floodgates for unlicensed buyers. Improper Data Collection They request EIN, NPI, and tax exemption documents  while not verifying any of them. That’s sensitive, government-issued data — yet they have no stated process for credential validation or secure storage. Angle:  They’re harvesting federally linked identifiers without a compliance framework. That alone could violate FTC Section 5 (unfair/deceptive acts)  and HIPAA-adjacent data handling expectations  if health providers are involved. Privacy Policy Conflict their April 2025 “policy” is boilerplate Shopify junk. It admits to “selling/sharing personal identifiers for marketing.” That creates a fatal contradiction: they collect EINs and NPIs under the guise of professional verification, then use a privacy policy that allows reselling of identifiers. Angle:  They’re effectively building a marketing list of verified-sounding “providers” to resell, while pretending it’s a compliance portal. Potential Fallout for Businesses By entering EIN or NPI data into that form, a business risks: Identity fraud  (those numbers can be used to open supplier accounts) Tax fraud exposure  (false filings or resale misrepresentation) Marketing spam / resale  (since the policy admits data sharing) Regulatory investigation  if Alpha BioMed uses that data to make provider claims Discrepancies in Alpha BioMed’s Contact Information between their 'Providers' Website and Main Website The two numbers : one is (888) 890-8143  (main site). The provider's website shows (949) 867-6165 . Two different toll-free / area codes. That mismatch creates trust issues. Multiple links (main site and portal) both claim to be “official,” but have different contact info. That’s sloppy or intentionally ambiguous. If the portal uses area code 949 (Southern California) rather than toll-free 888, that could indicate a separate (or sub-contracted) line. If they don’t clearly explain that difference, it weakens their claim of a singular coherent operation. Pattern of Risk and Regulatory Evasion The investigation into Alpha BioMed Labs  reveals a pattern consistent with deceptive marketing practices and potential regulatory violations. Although the company presents itself as a “U.S.-based manufacturer” of pharmaceutical-grade peptides, the evidence tells a different story: inconsistent contact details, unverifiable manufacturing claims, and public dosing instructions for substances that are not FDA-approved. The firm’s dual website infrastructure — split between a retail-facing Shopify storefront and a “provider-only” registration portal — allows consumers to access and purchase peptides with minimal verification. Features such as the “Not Sure” option on reseller applications, the public release of dosing and reconstitution guides, and frequent therapeutic claims (“accelerates healing,” “improves metabolism”) indicate that Alpha BioMed is intentionally marketing unapproved drugs under the guise of “research chemicals.” Furthermore, the absence of verifiable FDA registration, lack of ISO or GMP certifications, inconsistent COA documentation, and reliance on Shopify Payments (which prohibits such products) highlight systemic noncompliance. Even the mismatched phone numbers, recycled templates, and unverifiable test reports point toward an operation optimized for sales rather than safety or transparency. In short, Alpha BioMed Labs  exemplifies the growing class of online “research peptide” vendors that blur the line between laboratory use and human application. The inconsistencies and violations outlined in this report merit closer scrutiny by regulators, payment processors, and consumers alike. Until verifiable documentation and compliance measures are produced, Alpha BioMed’s operations should be treated as high-risk and potentially misleading  within the health and biotech marketplace. FDA Crackdown: Three Peptide Companies Cited for the Same Violations Seen at Alpha BioMed Here are the top 3 companies that has been cited for the same violations seen at Alpha BioMed Prime Vitality, Inc. (dba Prime Peptides) WARNING LETTER 695156 (Dec 10, 2024) Direct link to Warning letter: U.S. Food and Drug Administration Despite labeling “for research purposes only,” the site’s content showed intended human use/disease treatment language. Violation: unapproved new drugs under FD&C Act. Summit Research Peptides WARNING LETTER 695607 (Dec 10, 2024) Direct link to warning letter: U.S. Food and Drug Administration The FDA found that despite “research only” labeling, the evidence showed they intended human use. Xcel Research LLC WARNING LETTER 695156 (Dec 10, 2024)  Direct link to Warning letter: U.S. Food and Drug Administration Violated 505(a) & 301(d) of FD&C Act for unapproved new drugs. Prime Vitality, Inc. (dba Prime Peptides) Warning Letter Highlighting their Violations: Summit Research Peptides Warning Letter Highlighting Their Violations: Xcel Research LLC Warning Letter Highlighting their Violations: All findings and supporting evidence referenced in this report are sourced from publicly available records. Any attempt to alter or remove such material may constitute interference with public documentation and will be noted for compliance review. Individuals who have experienced deceptive or unauthorized practices involving Alpha BioMed Labs are encouraged to file a report using our intake form for review and documentation. Submissions may be evaluated for potential escalation to a coordinated consumer complaint or class action proceeding if sufficient evidence is established.

COMPLETE SCAM WATCHING REPORT Company Details: Sublime MD Entity:  Sublime MD / Sublime Medical Aesthetics & Dermatology (also operating under “Sublime Vitality”) Website:   https://sublimemd.com/ Domains Reviewed:   sublimemd.com | sublimevital.com | sublimemd.myshopify.com Lead physician / listed founder/leader:  Dr. Ronnie N. Dawood, MD (Meet the Doctors page).   sublimemd.com Addresses: 7095 Indiana Ave, Suite 210, Riverside, CA 92506.   sublimemd.com 255 Terracina Blvd, Suite 206, Redlands, CA 92373.   sublimemd.com 26342 Oso Parkway, Suite 204, Mission Viejo, CA 92691.   sublimemd.com Main phone : (951) 222-2212  (Riverside).   sublimemd.com Other location phones: (909) 792-8600 (Redlands), (949) 367-1115 (Mission Viejo).   sublimemd.com Public email shown in social content : info@sublimemd.com   Employees: 11-50 listed Social Media: Instagram: @sublimemd https://www.instagram.com/sublimemd/ Facebook: Sublime MD - Sublime Medical Aesthetics & Dermatology https://www.facebook.com/p/Sublime-MD-Sublime-Medical-Aesthetics-Dermatology-100037903764777/ Scam Score A 1-star rating represents the lowest tier in our trust scale and signals high probability of deception, non-compliance, or consumer harm. Vendors in this category exhibit one or more of the following: Verified false or misleading claims about origin, purity, or manufacturing. Unverifiable lab documents (missing accreditation, self-issued, or forged). Violations of federal or platform policies (FDA, FTC, Shopify, Stripe, etc.). Mismatch between corporate filings, claimed experience, and public data. Evidence of dosing/reconstitution instructions implying human use despite “research only” disclaimers. Impact: This low of a trust score automatically places the entity on ScamWatching.org  red-flag status  🚩— meaning the brand is considered untrustworthy until independently verified . Listings under this score are recommended for public exposure, platform reporting, and community alerting . SUBLIME MD PEPTIDES GENERAL OVERVIEW Sublime MD publicly presents itself as a dermatology and aesthetic clinic but simultaneously markets and distributes a broad range of unapproved injectable peptides  through its linked brand, Sublime Vitality . The peptide catalog includes substances such as BPC-157, TB-500, MOTS-C, Melanotan II, GHK-Cu, HGH, IGF-1 LR3, Semaglutide, Tirzepatide, and Retatrutide —several of which are identified by the FDA as Category 2 high-risk compounds  unsuitable for compounding or consumer sale. The public evidence shows a consistent pattern of non-compliant and deceptive marketing behavior  designed to create the appearance of medical legitimacy while avoiding pharmaceutical oversight. SUMMARY ASSESSMENT Sublime MD and its affiliate Sublime Vitality operate a high-risk peptide sales network using fabricated testimonials, unverified “third-party testing” claims, and unregistered compounding activities to promote unapproved injectable drugs for human consumption under the guise of medical aesthetics. Primary risk vectors: Unapproved Drug Distribution Offers multiple FDA-flagged peptides for injection, listed with vial sizes and BAC water pairing. No Certificates of Analysis, lot numbers, or lab verification links are provided. False Quality and Compliance Claims Asserts “Section 503A compliance” and “third-party testing,” yet there is no record  of Sublime Vitality or Sublime MD on the FDA 503B Outsourcing Facility Registry or the California Board of Pharmacy’s licensed compounder list. The firm’s operations—bulk orders and rapid fulfillment—contradict 503A’s patient-specific limitations. Consumer-Directed Misbranding The “Dr Skinny Shot”  page advertises telemedicine weight-loss injections (Semaglutide, Tirzepatide, Ozempic®, Mounjaro®) and guarantees shipping within 48 hours. These claims demonstrate patient-direct sales of prescription or compounded drugs without visible pharmacy registration. PRODUCTS AND CLAIMS Offerings: Full range of injectable peptides, including BPC-157, TB-500, GHK-Cu, MOTS-C, Melanotan II, GHRP-2, GHRP-6, CJC-1295, Ipamorelin, Tesamorelin, NAD⁺, IGF-1 LR3, HGH, Semaglutide, Tirzepatide, and Retatrutide.  Catalog also features peptide “stacks” (BPC-157/TB-500 Blend, “Glow Protocol Blend”) paired with BAC water for reconstitution — marketed as ready-to-use vials rather than research reagents. Claim Language: Therapeutic phrasing appears across pages — “supports recovery,” “enhances skin regeneration,” “improves metabolism and weight loss,” “promotes tissue healing,”  and “delivers precision peptide therapy.”  The copy repeatedly positions these peptides as patient-care solutions  and practice-ready treatments , not laboratory materials. Dosing Guides: No open “Dosing Guide” page is visible, but clinical dosing is embedded within product text (“reconstitute to precise concentrations tailored to each patient,” “includes 3 mL BAC water for easy mixing”). The Dr Skinny Shot  page extends this to GLP-1 products, showing explicit mg strengths, weight-loss percentages, and shipping timelines , all characteristic of human-use dosing guidance. Reconstitution Info: Listed directly in product descriptions — every peptide vial “paired with bacteriostatic water” and “reconstituted to precise concentrations.” This constitutes public instruction for injectable preparation and subcutaneous use. Purity Claims: Every SKU references “third-party tested,” “lab tested,” “U.S. made,”  or “RX-quality peptides.”  No actual COAs, lab identifiers, or traceable certificates appear. The phrasing mirrors generic foreign-supplier marketing language  (≥ 99 % purity claims without verification), suggesting unverifiable or imported testing data. VIOLATIONS AND RED FLAGS They repeatedly describe Sublime Vitality as a “US-based finisher of RX-quality peptides meeting Section 503A requirements,”  but provide no FDA registration numbers, no CGMP or ISO-17025 certificates, no physical laboratory address, and no batch-level Certificates of Analysis. FDA’s 503B Outsourcing Facility registry shows no listing for any “Sublime MD” or “Sublime Vitality.” That absence, paired with marketing language such as “bulk order,” “rapid 48-hour fulfillment,”  and “U.S. made and lab tested,”  forms a classic red-flag combination indicating unregistered sterile production and deceptive quality claims. Sources : sublimemd.com / sublimevital.com Therapeutic and Medical Claims Public peptide catalog lists BPC-157, TB-500, GHK-Cu, MOTS-C, Melanotan II, PT-141, IGF-1 LR3, HGH, AOD-9604, CJC-1295, Ipamorelin, Tesamorelin, Semaglutide, Tirzepatide, and Retatrutide—each accompanied by strengths, dosing context, and “paired with BAC water” instructions. Product blurbs use therapeutic disease-type language: “enhances recovery,” “improves metabolism,” “supports skin regeneration,” “reduces inflammation.” Those are structure/function and disease claims for substances that have no FDA approval, placing every listing squarely in “unapproved and misbranded drug” territory. Source: sublimemd.com/peptides-offered Dosing and Distribution Conduct Both Sublime MD and Sublime Vitality operate telemedicine-plus-shipping workflows. The Dr Skinny Shot page promises “Prescribed in-office or online & shipped within 48 hours,”  listing Ozempic®, Mounjaro™, and generic Semaglutide/Tirzepatide. Meanwhile, the peptide catalog promotes “personalized dosing” and “bulk orders for providers.” That dual model—mass stock supply plus patient-direct shipment—violates 503A’s patient-specific limitation and functions as unregistered 503B-level distribution. Source: sublimemd.com / sublimevital.com False Purity and Testing Assertions Every SKU advertises “third-party tested for purity and sterility”  and “lab verified ≥ 99 % purity.” No public lab name, certificate number, or assay data appear anywhere on-site. The wording mirrors generic foreign supplier templates, suggesting unverifiable import certificates rather than domestic analytical testing—another red flag for misbranding and adulteration.  Source: sublimevital.com High-Risk Compounds and Category-2 Violations The catalog includes peptides—BPC-157, Melanotan II, MOTS-C, TB-500—that the FDA designates as Category 2 bulk substances due to safety, impurity, and immunogenicity risks. Compounding or distributing these for injection constitutes manufacturing of unapproved new drugs under 21 U.S.C. § 355 and § 352. Source: U.S. Food and Drug Administration Deceptive Testimonials (Consumer Use Evidence) The Sublime Vitality site hosts fake “customer recovery” reviews describing healing, weight-loss, and skin improvements after peptide use. Such testimonials confirm intended human use, contradict the “not for human consumption” disclaimer in the footer, and qualify as misleading advertising and evidence of unapproved drug promotion.  Source: sublimevital.com Regulatory Significance Each of these behaviors—unapproved peptide claims, lack of COAs, unregistered sterile distribution, and consumer testimonials—mirrors patterns cited in FDA warning letters against peptide vendors marketing GLP-1 analogs and healing peptides. Taken together, Sublime MD / Sublime Vitality meet the threshold for unapproved drug manufacturing, misbranding, and deceptive marketing  under the Federal Food, Drug, and Cosmetic Act. Professional Licensing Conflict and Jeopardy for Unlawful Peptide Commerce A verified National Provider Identifier (NPI #1851593065)  confirms that Dr. Ronnie Nathan Dawood  is an actively licensed physician in California, practicing internal medicine and dermatology at 26342 Oso Parkway Suite 204, Mission Viejo, CA 92691.This verification establishes that Sublime MD operates under a state-issued medical license , which carries explicit ethical and statutory obligations under California Business & Professions Code § 4170-4172  and 21 U.S.C. §§ 331, 352, 355 . Despite that licensure, Sublime MD / Sublime Vitality  openly markets and distributes non-FDA-approved “research peptides”  such as BPC-157, TB-500, Melanotan II, MOTS-C, and GHK-Cu , often described as “U.S. made and lab tested”  but showing no traceable Certificates of Analysis or FDA-registered manufacturing source. Multiple lot descriptions and phrasing patterns used on the Sublime Vitality site match foreign-supplier templates common to Chinese peptide exporters , suggesting that the materials being resold are imported research compounds , not products produced in a licensed U.S. facility. Because Dr. Dawood and any affiliated clinicians hold active state medical licenses, their participation in the sale or distribution of imported research-grade peptides exposes those licenses to disciplinary action . Under California Medical Board regulations, a physician who prescribes, sells, or profits from unapproved foreign drug substances  may be cited for “unprofessional conduct,” “distribution of adulterated or misbranded drugs,”  and “gross negligence.” Such conduct can lead to license suspension, revocation, or mandatory probation  if regulators determine the products originated from non-certified overseas suppliers or were represented as therapeutic without FDA clearance. In effect, the use of an active medical license to market peptides sourced from China transforms a civil labeling violation into a professional-license offense . It directly conflicts with both FDA import regulations (21 CFR Part 1 Subpart E)  and the California Medical Practice Act , which prohibit licensed practitioners from participating in the sale or promotion of unapproved foreign pharmaceuticals. Pattern of Risk and Regulatory Evasion The investigation into Sublime MD  and its affiliated brand Sublime Vitality  reveals a coordinated pattern of regulatory evasion, deceptive medical marketing, and potential misuse of active physician licenses . Although the organization presents itself as a “U.S.–based finisher of RX-quality peptides meeting Section 503A standards,”  public records and site data point to unregistered manufacturing, unverifiable sourcing, and unapproved drug promotion. Sublime MD operates a dual-infrastructure model —a clinical website ( sublimemd.com ) that advertises “prescribed and shipped”  peptides and GLP-1 products, and a wholesale platform ( sublimevital.com ) offering “bulk ordering,” “2-day shipping,”  and “third-party tested”  peptide vials. This structure blurs the line between medical practice and unlicensed pharmaceutical distribution, allowing direct-to-consumer sales of non-FDA-approved peptides  under a medical façade. The peptide catalog lists a wide array of high-risk compounds— BPC-157, TB-500, MOTS-C, Melanotan II, GHK-Cu, PT-141, HGH, IGF-1 LR3, AOD-9604, and GLP-1 analogs (Semaglutide, Tirzepatide, Retatrutide) —each presented with dosing strengths, reconstitution language, and therapeutic claims such as “enhances recovery,” “improves metabolism,”  and “restores youthful skin.” These are disease and structure/function claims  for substances not approved for human use , thereby classifying them as unapproved and misbranded drugs  under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 331, 352, 355) . Further compounding the risk, the business employs a telemedicine + rapid-shipment workflow , promising prescription approval and delivery within 48 hours—an operational pattern consistent with 503B outsourcing behavior despite no FDA registration. This model violates 503A’s patient-specific limitations , exposing the clinic to enforcement for unregistered sterile production  and improper distribution of compounded drugs . Critically, the lead physician Dr. Ronnie Nathan Dawood (NPI # 1851593065)  is a licensed California medical doctor , which introduces a deeper compliance breach. While this confirms professional status, it simultaneously imposes legal and ethical restrictions against the sale or resale of research-grade peptides , especially those imported from foreign suppliers. The Sublime Vitality catalog mirrors Chinese peptide-export language  (“99 % purity,” “lab tested,” “bulk available”), suggesting overseas sourcing and repackaging rather than FDA-regulated manufacture. Under California Medical Board and FDA statutes, participation by a licensed physician in the sale or promotion of unapproved foreign drugs constitutes unprofessional conduct —a disciplinary ground that can lead to license suspension or revocation . In essence, Sublime MD and Sublime Vitality exhibit a dual pattern of violation: Regulatory deception  through the marketing and sale of unapproved peptide drugs under false claims of U.S. manufacture and compounding compliance; and Professional licensing jeopardy  by using an active medical license to legitimize and profit from imported “research peptides” outside lawful pharmaceutical channels. Until verifiable COAs, FDA registrations, and state compounding licenses are publicly produced, Sublime MD’s peptide operations should be considered high-risk, non-compliant, and in violation of both federal drug law and state medical-licensure standards . FDA Crackdown: Three Peptide Companies Cited for the Same Violations Seen at Sublime MD Here are the top 3 companies that has been cited for the same violations seen at Sublime MD  US Chem Labs ( uschemlabs.com ) Warning Letter (Feb 7, 2024) Direct link to warning letter: U.S Food And Drug Administration Site offered semaglutide, tirzepatide and thymalin to U.S. buyers; despite “research only/not for human consumption” labels, the overall marketing established intended human use. FDA called the products unapproved new drugs  and misbranded  (no adequate directions for use for laypeople) GLP-1 Solution ( glp1solution.store ) Warning Letter (Sept 9, 2025) Direct link to warning letter: U.S Food And Drug Administration Offered retatrutide, semaglutide, tirzepatide  as compounded drug products. FDA states retatrutide cannot be used  under 503A or 503B conditions, so the firm’s products are unapproved  and misbranded ; the letter also details failures to meet 503A/503B conditions and labels with inadequate directions for use. Veronvy (veronvy.com) Warning Letter (Dec 10, 2024) Direct link to warning letter: U.S Food And Drug Administration  Marketed “GLP-1” weight-loss drops to consumers, claiming “FDA approved” and making efficacy promises. FDA called them unapproved  and misbranded  drugs, flagging deceptive “FDA APPROVED” graphics and weight-loss claims. While these were oral drops rather than vials, the violation pattern is identical: human-use claims for non-approved products, misleading marketing, interstate sales.  US Chem Labs  Warning Letter Highlighting their Violations: GLP-1 Solution Warning Letter Highlighting their Violations: Veronvy  Warning Letter Highlighting their Violations: All findings and supporting evidence referenced in this report are sourced from publicly available records. Any attempt to alter or remove such material may constitute interference with public documentation and will be noted for compliance review. Individuals who have experienced deceptive or unauthorized practices involving Alpha BioMed Labs are encouraged to file a report using our intake form for review and documentation. Submissions may be evaluated for potential escalation to a coordinated consumer complaint or class action proceeding if sufficient evidence is established.

Short version: This “brand” looks like a CN-based UEESHOP storefront flipping peptides/SARMs/steroids with zero corporate transparency and no public COAs. Modpeptide / ModHealthLab — key findings Company & structure:  No legal entity disclosed anywhere. The site footer is the generic UEESHOP “MY SHOP”  template; no address, no registrant. Contact page lists PRC WhatsApp numbers and @ 126.com  emails (classic CN ops). MY SHOP+2MY SHOP+2 Owners:  Not stated. Only names shown are “Tephanie / Tiffany” on the contact page—likely storefront reps, not beneficial owners. MY SHOP Domains/aliases:  Primary: modpeptide.com . Variants & scans exist (e.g., mod-peptide.com / mod-peptides.com ) with low trust scores from automated scanners. ScamAdviser+2ScamAdviser+2 Catalog:  Peptides (BPC-157, IGF-1 LR3, GHRP-2, MT-2), steroids , HGH 191aa , HCG —the whole gray-/black-market menu. Pages make medical/benefit claims. MY SHOP+5MY SHOP+5MY SHOP+5 Dosing instructions?  None found on-site. Product blurbs hype “benefits” but no explicit dosing tables or calculators. (I searched pages & terms directly.) MY SHOP+1 Reconstitution instructions?  None found on-site. (Again, checked across product/collection pages.) MY SHOP COAs:   No COA library  or per-lot COAs located anywhere on the site. Contrast with legit vendors that host COA libraries; this one doesn’t. Third-party “trust” sites flag their domains/variants, reinforcing caution. MY SHOP+2ScamAdviser+2 Marketing: Facebook page  “Modpeptide Lab” pushing promos; group  “Mod Peptides” focused on weight loss/GLP-1 chatter. Facebook+1 “Recruit partners sincerely” page = affiliate/referral program. Couponing shows up on Knoji. MY SHOP+1 No blog; thin SEO content. Where do they claim peptides come from?  They don’t. CN WhatsApp + 126.com  emails + UEESHOP strongly imply China-based supply . No lab names or origin claims anywhere. MY SHOP+1 Revenue (est.):  Public traffic isn’t disclosed. StoreLeads ranks the domain ~ 695k  in UEESHOP Nutrition—i.e., low. Using conservative e-com assumptions (AOV $120–$250; CR ~0.8–1.5%): with 5k–20k sessions/mo they’d clear roughly $9k–$35k/mo . Replace with real traffic when/if we get it. Store Leads Compliance posture:  High risk. They list prescription-only  agents (HGH, HCG, steroids) alongside “research” peptides and GLP-1 adjacent chatter. FDA has explicitly warned about online vendors selling unapproved GLP-1s marketed “for research only.” Context isn’t a strike on them specifically, but the shoe fits. U.S. Food and Drug Administration ModHealthLab note:  Their domain currently renders a home-gym equipment  storefront branded “Primpulsefit,” not a peptide site. Only 2 reviews on Trustpilot (2024). Looks like a pivot/repurpose or domain parking, not an active peptide competitor. Mod Health Lab+1 Company name:  Modpeptide (aka “Mod Peptides”, “Modpeptide Lab”); ModHealthLab (historic/alias?) Primary domain(s):   https://modpeptide.com  ; https://www.modhealthlab.com Known aliases/DBA:  “Modpeptide Lab” (Facebook page), “Mod Peptides” (Facebook group); multiple look‑alike domains reported by 3rd‑party scanners (e.g., mod-peptide.com , mod-peptides.com ) 1) Company Snapshot Field Findings Company legal name Not disclosed on site. Footer shows UEESHOP storefront template; no registered entity named. Country / State of registration Not stated. Contact page lists China-based WhatsApp numbers and @ 126.com emails (common CN mail), implying China. Corporate structure (LLC/C‑Corp/etc.) Unknown. Parent/Subsidiaries None listed. Owners / key principals Not disclosed; site lists “Tephanie / Tiffany” on contact page. Addresses (registered & operational) None published. Contact info (email/phone) WhatsApp: +86 18213818287, +86 13424154314; Emails: ynherstar@126.com , ynherstar03@126.com  (from modpeptide.com/contact-us ). Incorporation / SOS links None found. Payment methods accepted Not enumerated publicly prior to checkout. Claimed sourcing (country/lab) No explicit claim; CN contact details suggest China-based supply. COA policy (real/update cadence) No COA library or per‑lot COAs located on site. Dosing instructions on site? None located (no dosing pages; product blurbs contain benefit claims). Reconstitution instructions on site? None located. Marketing channels (site/SEO/social/ads/affiliates) Site catalog; Facebook page “Modpeptide Lab”; Facebook group “Mod Peptides”; couponing via 3rd‑party sites; “Recruit partners sincerely” affiliate page. Estimated traffic (Similarweb, etc.) Low; Storeleads ranks modpeptide.com ~695k globally among UEESHOP nutrition stores (directional). Revenue estimate (method) Not enough public data; see Section 6 for modeled ranges. 2) Ownership & Corporate Records Beneficial owners / managers:  Not disclosed. Secretary of State / Companies House filings:  None located. Other linked companies/domains:  Variants detected by third‑party scanners ( mod-peptide.com , mod-peptides.com ). Storefront shows UEESHOP platform markers. Notes:  Contact names "Tephanie / Tiffany" with PRC phone codes; suggests a CN wholesaler/dropship operation rather than a US entity. Evidence: Contact page: https://modpeptide.com/pages/contact-us UEESHOP footer throughout site: https://modpeptide.com/ Third‑party risk scanners for variants: https://www.scamadviser.com/check-website/mod-peptide.com  , https://www.scamadviser.com/check-website/mod-peptides.com 3) Products & Compliance Posture Product catalog highlights:  Peptides (BPC‑157, IGF‑1 LR3, GHRP‑2, Melanotan II), SARMs, steroids , HGH vials, HCG  powder. Disclaimers (research-only, not for human use, etc.):  No prominent research‑only banner found; product pages include medical/benefit claims (e.g., MT‑2, BPC‑157, HGH pages). Shipping / returns / TOS:  Generic e‑commerce policies; free shipping banner over $199. Dosing/Reconstitution policy:  No specific dosing or reconstitution instructions located on the site. COAs:  No COA library or batch‑level COAs surfaced on site/product pages. Evidence: Catalog landing: https://modpeptide.com/  ; Collections: https://modpeptide.com/collections/peptide  , https://modpeptide.com/collections/steroids Example products: HGH 191aa page, BPC‑157 page, GHRP‑2 page. 4) Marketing & Distribution Website tech (CMS, cart, processors):  UEESHOP template ("MY SHOP"), multi‑language widget, basic cart. SEO summary:  Thin product copy; no blog section detected. Content/blog cadence:  None. Email/SMS funnels:  Newsletter modal not observed; couponing via third‑party deal sites. Paid ads:  Meta Ads Affiliates/influencers:  “Recruit partners sincerely” page indicates referral/affiliate push. Socials: Facebook page: “Modpeptide Lab” (promo posts, GLP‑1 pitches). Facebook group: “Mod Peptides” weight‑loss group. Evidence: FB page: https://www.facebook.com/p/Modpeptide-Lab-100093981766602/ FB group: https://www.facebook.com/groups/modpeptides/ Coupon aggregator: https://modpeptides.knoji.com/promo-codes/ “Recruit partners sincerely”: https://modpeptide.com/pages/recruit-partners-sincerely 5) Quality Signals COA authenticity checks:  No public COAs to verify. Lot traceability:  None provided. Customer feedback:  Mixed/low‑volume chatter on coupon/review aggregators; third‑party scanners flag variants (low trust scores). Regulatory flags:  Product lineup (HGH, HCG, steroids) raises risk; FDA (2024–2025) has broadly warned online vendors selling unapproved GLP‑1s and research‑labeled drugs—contextual risk. Evidence: Scanner examples: https://www.scamadviser.com/check-website/mod-peptide.com  ; https://www.scam-detector.com/validator/modpeptide-com-review/ FDA context: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss 6) Traffic & Revenue Modeling Traffic est.:  Low. Storeleads ranks modpeptide.com ~695k among UEESHOP nutrition stores; public traffic not disclosed. AOV guess:  If cart resembles typical research‑peptide baskets, $120–$250. Conv. rate assumption:  0.8–1.5% (thin content, low trust indicators). Model:  revenue = sessions × CR × AOV Result (illustrative):  If 10k sessions/mo × 1% × $175 ≈ $17.5k/mo ; if 5k sessions, ≈ $8.8k/mo ; if 20k sessions, ≈ $35k/mo . Replace with better traffic data when available. Notes/Assumptions:  These are directional; plug real traffic when we capture Similarweb/GA leaks. 7) Risk & Opportunities Weak spots:  No COAs; heavy medical claims; CN contact details; steroids/HGH/HCG SKUs; thin content; low trust‑score chatter; no corporate transparency. Differentiation ideas:  Lead with verified COAs (test lab named, dates, lot hashes), visible disclaimers, robust QC pipeline, US‑based entity disclosures, better copy, education blog, transparent shipping & returns, verified reviews. Legal/compliance exposure:  Elevated, given FDA posture on research‑labeled GLP‑1s and online sales of prescription‑only substances. 8) Source Log (links + dates) modpeptide.com (catalog, footer, contact) — accessed 2025‑10‑16 Contact page (WhatsApp +86, @ 126.com emails): https://modpeptide.com/pages/contact-us  — 2025‑10‑16 Collections (peptides/steroids): https://modpeptide.com/collections  ; /collections/peptide ; /collections/steroids — 2025‑10‑16 Product examples: BPC‑157, IGF‑1 LR3, GHRP‑2, HGH 191aa — 2025‑10‑16 “Recruit partners sincerely”: https://modpeptide.com/pages/recruit-partners-sincerely  — 2025‑10‑16 Storeleads UEESHOP rank: https://storeleads.app/reports/ueeshop/category/Health/Nutrition  — 2025‑10‑16 Coupon aggregator (signals): https://modpeptides.knoji.com/promo-codes/  — 2025‑10‑16 Facebook page: https://www.facebook.com/p/Modpeptide-Lab-100093981766602/  — 2025‑10‑16 Facebook group: https://www.facebook.com/groups/modpeptides/  — 2025‑10‑16 3rd‑party scanners: https://www.scamadviser.com/check-website/mod-peptide.com  ; https://www.scam-detector.com/validator/modpeptide-com-review/  ; https://www.scamadviser.com/check-website/mod-peptides.com  — 2025‑10‑16 FDA GLP‑1 warning context: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss  — 2025‑10‑16 ModHealthLab current site (gym equipment storefront): https://www.modhealthlab.com/  — 2025‑10‑16 Trustpilot (Modhealthlab): https://www.trustpilot.com/review/modhealthlab.com  — 2025‑10‑16

Status:  Reported / Under Review TL;DR Roca Labs marketed a “gastric bypass alternative” supplement with misleading weight loss claims. The FTC found their advertising deceptive and is issuing refunds totaling ~$409K to affected consumers. Federal Trade Commission Key facts Product / brand:  Roca Labs “weight-loss supplement” Date of action / ruling:  July 2025 (FTC refund announcement) Federal Trade Commission Amount refunded:  > $409,000 to consumers Federal Trade Commission Wrongdoing identified:  False claims of dramatic weight loss / gastric bypass effect; misleading testimonials; review manipulation Federal Trade Commission Evidence / sources FTC press release about the refunds and enforcement action Federal Trade Commission Supplement recall and health fraud databases show repeated enforcement on similar claims. U.S. Food and Drug Administration+1 Reporter quote (community submission) “I bought that ‘miracle’ Roca supplement thinking it’d mimic surgery. After 3 months — no weight loss and constant hunger. I saved my purchase screenshot and their original ad claims.”

Status:  Reported / Under Review TL;DR:   Some Ozempic injections in circulation are counterfeit — FDA is flagging at least one lot (PAR0362 / serials starting 51746517) as illegitimate. Use caution with ANY semaglutide bought outside certified supply chains. Key facts: Date flagged:  April 2025 New York Post Suspect lot / serials:  PAR0362; serials starting 51746517 New York Post Scope:  hundreds of units seized by FDA from non-authorized distribution channels New York Post Potential harm:  Unknown composition; risk from injection of unknown mixtures Evidence (source links): FDA / news announcements on counterfeit Ozempic warning New York Post Manufacturer & distributor statements from Novo Nordisk about tracing counterfeit batches New York Post Reporter / user claim: “I purchased what I thought was discounted Ozempic online. The vial lot number was PAR0362 — I flagged that to FDA and discovered it’s one of the suspected counterfeit lots.” Suggested action / calls to readers: If you got Ozempic from a non-pharmacy source, compare your vial’s lot/serial. Upload your proof (photos, transaction) so others can cross-check and build a list.

Status: Reported / Under Review TL;DR Community reports and chain-analysis firms show YZY (Yeezy / Ye) memecoin spiked and then collapsed within hours of launch — thousands of traders lost money while a very small number of wallets profited heavily. Multiple news outlets flagged suspect insider trades and liquidity setup that resemble rug-pull mechanics. Cointelegraph Key facts Project / Token:  YZY (Yeezy / Ye memecoin). Cointelegraph Date of launch & crash:  August 21, 2025 (rapid pump then >50% crash same day). Yahoo Finance Reported impact:  Tens of thousands of traders realized losses; analytics firms reported that a small cluster of wallets profited heavily. Cointelegraph Red flags noted by analysts:  large insider holdings, atypical liquidity pairing, suspicious wallet activity / early profit-taking. CCN.com Evidence (links / sources) Cointelegraph coverage summarizing wallet losses and on-chain analytics. Cointelegraph Wired overview of YZY launch, pump, and crash with Nansen / on-chain metrics. WIRED Additional analysis threads from on-chain sleuths Reporter statement (community submission) “I bought in on launch hype and watched it pop then dump in under an hour. My order shows losses and the on-chain charts show obvious insider/whale profit wallets.” Suggested action for readers If you lost funds: collect TX hashes, exchange screenshots, and Submit a Report . We will add verified reports to this entry.

Status:  Reported / Under Review TL;DR On-chain watchers flagged Aqua (a Solana project) after large SOL movements were spotted leaving liquidity pools and roughly $4–5M worth of SOL was moved through intermediary addresses and split across exchanges — community sleuths suspect a coordinated rug/exit. Bitget and on-chain commentators posted initial alerts. Bitget+1 Key facts Project / Token:  Aqua (Solana project; promoted in the Solana ecosystem by several tooling / analytics providers). Bitget Date of incident flagged:  Early September 2025 (reporting and alerts surfaced around Sept 9). Bitget Reported flow:  ~21,770 SOL moved into intermediaries and split to multiple exchanges per on-chain notes — possible laundering pattern using mixer/bridge flows. Bitget Evidence (links / sources) Bitget alert note summarizing the suspicious SOL transfers and KOLs promoting the project. Bitget SolidusLabs / on-chain analysis context on typical Solana rug mechanics (for reference). Solidus Labs Reporter statement (community submission) “We saw a flagged transfer thread and some KOLs go quiet. We grabbed the wallet snapshots and saved the on-chain traces. Posting here so others can check their exposure.” Suggested action for readers If you held Aqua tokens, paste TX hashes & wallet addresses into the report form so admins can correlate flows and produce a combined victim list for exchanges/regulators.

In the ever-evolving landscape of business models, the terms "Multi-Level Marketing" (MLM) and "Pyramid Scheme" often create confusion among consumers and potential investors. While both involve recruiting individuals to sell products or services, the fundamental differences can determine whether a business is legitimate or a scam. This blog post aims to clarify these distinctions, particularly in the context of modern case studies involving health products and cryptocurrency MLMs. What is MLM? Multi-Level Marketing (MLM) is a business model where individuals earn income through direct sales of products and by recruiting new members into the business. The key feature of MLM is that participants can earn commissions not only from their sales but also from the sales made by their recruits, creating a tiered structure of income. MLMs often promote legitimate products, ranging from health supplements to beauty products. However, the success of participants can vary widely, and the model can sometimes lead to financial losses for many involved. What is a Pyramid Scheme? Pyramid schemes, on the other hand, are illegal in many countries and are characterized by the promise of high returns primarily for recruiting new members rather than selling actual products or services. In a pyramid scheme, the focus is on recruitment, and the money flows upward to those at the top of the pyramid, leaving those at the bottom with little to no chance of recovering their investments. The lack of a legitimate product or service is a significant red flag that distinguishes pyramid schemes from MLMs. Participants often find themselves in a cycle of recruitment, where the only way to make money is to bring in more people, leading to inevitable collapse when recruitment slows. Key Differences Between MLMs and Pyramid Schemes Product Focus : MLMs typically have a legitimate product or service that is sold to consumers, while pyramid schemes often lack a viable product and focus solely on recruitment. Income Structure : In MLMs, income is generated through sales and commissions from recruits. In pyramid schemes, income is primarily derived from new member fees, with little emphasis on product sales. Sustainability : MLMs can be sustainable if they have a solid product and a genuine market. Pyramid schemes are inherently unsustainable, as they rely on continuous recruitment. Legality : MLMs operate within legal frameworks, while pyramid schemes are illegal in many jurisdictions. Modern Case Studies: Health Products and Crypto MLMs Health Products One of the most prominent examples of MLMs in the health sector is Herbalife. The company has faced scrutiny and legal challenges over its business practices, with critics arguing that it operates more like a pyramid scheme. However, Herbalife maintains that it offers legitimate products and adheres to MLM regulations. This case highlights the fine line between MLM and pyramid schemes, as the company's success relies heavily on recruitment and the sales of its health products. Crypto MLMs The rise of cryptocurrency has also given birth to numerous MLMs that promise high returns on investments. One such example is BitConnect, which was widely criticized for its pyramid-like structure. Participants were encouraged to invest in the platform and recruit others, with the promise of substantial returns. Ultimately, BitConnect collapsed, leaving many investors with significant losses. This case serves as a cautionary tale for those considering involvement in crypto MLMs, emphasizing the importance of due diligence. How to Identify a Legitimate MLM To distinguish a legitimate MLM from a pyramid scheme, consider the following factors: Product Quality : Research the products being sold. Are they of high quality? Is there a genuine market demand for them? Earnings Disclosure : A legitimate MLM should provide clear information about potential earnings and the percentage of participants who achieve those earnings. Focus on Sales : Ensure that the business model emphasizes product sales rather than recruitment. If the primary focus is on bringing in new members, it may be a red flag. Regulatory Compliance : Check if the company complies with local laws and regulations regarding MLM practices. Conclusion Navigating the world of MLMs and pyramid schemes can be challenging, especially in today's market where new business models emerge rapidly. Understanding the differences between these two structures is crucial for anyone considering involvement in such ventures. By focusing on product quality, earnings transparency, and regulatory compliance, individuals can make informed decisions and avoid falling victim to scams. As the landscape continues to evolve, staying informed and vigilant is key. Whether exploring health products or the latest in cryptocurrency, always conduct thorough research and seek advice from trusted sources before making any commitments. A health supplement bottle showcasing its label and design In conclusion, while MLMs can offer legitimate business opportunities, the potential for scams remains high. By understanding the fine line between MLMs and pyramid schemes, individuals can protect themselves and make choices that align with their financial goals.

The 2018 Housing Crash marked a significant turning point in the real estate market, echoing the lessons learned from the 2008 financial crisis. As the housing market boomed, many believed they were building wealth through property investments. However, beneath the surface, fraudulent practices and speculative financing were rampant, leading to a crash that left many investors and homeowners in dire straits. This blog post will dissect the lead-up to the crash, the fraudulent practices that fueled it, and the individuals and families who ultimately got burned. The Lead-Up to the Crash In the years leading up to the 2018 Housing Crash, the real estate market experienced a rapid increase in home prices. Low-interest rates and a booming economy encouraged many to invest in real estate, believing it to be a surefire way to build wealth. However, this optimism was built on shaky foundations. Many buyers were lured into the market by the promise of quick profits and easy financing. Speculative home finance became the norm, with individuals purchasing properties not for long-term living but as short-term investments. This led to a surge in demand, driving prices even higher and creating a bubble that was destined to burst. The Rise of Fraudulent Practices As the housing market heated up, so did the prevalence of fraudulent practices. One of the most notorious was property flipping, where investors would buy homes, make minimal improvements, and quickly resell them at inflated prices. This practice not only distorted the market but also contributed to the unsustainable rise in home values. Additionally, lenders began to relax their standards, offering loans to individuals who may not have qualified under stricter guidelines. This included subprime mortgages, which were often given to borrowers with poor credit histories. The combination of easy credit and speculative buying created a perfect storm for the housing market. Speculative Home Finance Speculative home finance played a crucial role in the lead-up to the crash. Many investors were drawn to the idea of purchasing multiple properties, believing that they could sell them for a profit within a short period. This led to a surge in demand for homes, pushing prices to unsustainable levels. However, as more people entered the market with the intent to flip properties, the supply of homes began to outpace demand. When the market finally corrected itself, those who had invested heavily in speculative properties found themselves unable to sell, leading to significant financial losses. Who Got Burned? The fallout from the 2018 Housing Crash was widespread. Many first-time homebuyers, lured by the promise of easy wealth, found themselves underwater on their mortgages, owing more than their homes were worth. Families who had invested their life savings into properties faced foreclosure, while investors who had taken on significant debt to finance their purchases were left with empty homes and mounting bills. Moreover, the crash had a ripple effect on the economy. Construction workers, real estate agents, and other professionals who relied on a thriving housing market found themselves out of work as demand plummeted. The impact was felt not just in the housing sector but across various industries, highlighting the interconnectedness of the economy. Lessons Learned The 2018 Housing Crash serves as a stark reminder of the dangers of speculative investing and the importance of responsible lending practices. It underscores the need for both buyers and lenders to exercise caution and due diligence in the real estate market. Investors should be wary of the allure of quick profits and consider the long-term implications of their investments. Homebuyers must ensure they are financially prepared for the responsibilities of homeownership, rather than succumbing to the pressure of a booming market. A vacant suburban home signaling the aftermath of the housing crash The Role of Regulation In the wake of the crash, regulatory bodies took steps to prevent a similar situation from occurring in the future. Stricter lending standards were implemented, and oversight of the mortgage industry was increased. These measures aimed to protect consumers and ensure that the housing market remained stable. However, the effectiveness of these regulations remains a topic of debate. Critics argue that while regulations are necessary, they can also stifle growth and limit access to homeownership for those who may benefit from it. Striking a balance between regulation and market freedom is essential for a healthy housing market. Conclusion The 2018 Housing Crash was a complex event driven by a combination of speculative practices, fraudulent activities, and a lack of regulatory oversight. As the dust settles, it is crucial for both investors and homebuyers to learn from the past and approach the housing market with caution and responsibility. Understanding the dynamics of the market, recognizing the signs of a bubble, and being aware of the risks associated with speculative investing can help individuals make informed decisions. The lessons learned from the 2018 Housing Crash should serve as a guiding light for future generations, ensuring that the dream of homeownership remains attainable and sustainable for all.

The 2007-08 financial crisis remains one of the most critical economic events in modern history. The film "The Big Short" effectively brought this complex narrative into the public's view. It depicted how a few investors predicted the collapse of the housing market and turned it into profit, raising ethical questions about betting on disaster. Was this a grand conspiracy or simply a failure of a flawed system? In this post, we will explore the mortgage derivatives crisis, examining the motivations behind the actions of key players and the broader implications still felt today. Understanding the Mortgage Derivatives Mess At the core of the 2007-08 crisis was the rise of mortgage-backed securities (MBS) and collateralized debt obligations (CDOs). These financial products were created by bundling thousands of mortgages, which were then sold to investors hoping to mitigate risk. The idea was that pooling loans would spread the risk more evenly, making them safer investments. However, as home prices soared, lenders began issuing subprime mortgages to borrowers with poor credit histories. This practice significantly increased the rate of defaults. For example, nearly 10% of subprime mortgages defaulted in 2006, leading to a ripple effect throughout the economy. The complexity of these financial products made it challenging for investors to grasp their true risk level. Rating agencies were often overly optimistic, assigning high ratings to MBS and CDOs despite the underlying risks. For instance, in 2007, about 70% of all MBS were rated as "AAA," offering false security to investors who believed they were making wise financial choices. The Role of Key Players "The Big Short" showcases several key players who anticipated the market collapse and capitalized on it. Michael Burry, Steve Eisman, and the team at FrontPoint Partners conducted extensive research to unveil the mortgage market's flaws that others ignored. They recognized the housing bubble's unsustainability and began betting against it by purchasing credit default swaps (CDS), which acted like insurance against the failure of these securities. For example, Burry's fund, Scion Capital, invested over $1 billion in CDS, allowing him to profit significantly once the market crashed. While many investors were unaware of the impending doom, Burry and his colleagues’ foresight raised ethical questions about profiting from widespread suffering. As a result, countless homeowners and pension funds faced ruin, while these savvy investors navigated a system favoring the wealthy. A Predictable Gaming System Some argue that the lead-up to the crisis was not a grand conspiracy but rather a predictable outcome of a broken system that prioritized reckless behavior. Financial institutions were focused on short-term gains rather than long-term stability. This culture of greed was pervasive on Wall Street and resulted in a lack of accountability. Regulatory bodies struggled to keep pace with financial innovations, allowing risky practices to run unchecked. The combination of lax regulations and aggressive lending created the perfect storm for disaster. In 2007 alone, 1.5 million foreclosure filings were recorded in the United States, reflecting the systemic failures that led to the crisis. The Aftermath and Lessons Learned The aftermath of the 2007-08 crisis was devastating. It caused massive unemployment, a surge in foreclosures, and a global recession. In response, governments worldwide implemented broad reforms aimed at preventing a similar catastrophe. For example, the Dodd-Frank Act introduced new regulations, including higher capital requirements for financial institutions and increased oversight of derivatives trading. Despite these reforms, many experts remain skeptical about their effectiveness. A 2021 study revealed that almost 50% of financial experts believed the conditions that led to the crisis could easily resurface. It is crucial that we remember the lessons learned from this time to safeguard against future collapses. A crumbling house symbolizing the housing crisis The Ethical Dilemma of Short Selling The actions of those who made money from the market collapse raise vital ethical questions about short selling. While this can be a legitimate investment strategy, betting against the market can seem like profiting from others' suffering. Critics suggest short sellers create market instability, while supporters argue they help identify overvalued assets. The investors in "The Big Short" were not just opportunists; they recognized systemic failures and acted on their insights. Their actions, although controversial, underscore the importance of transparency and accountability in the financial system. Reflection on the Crisis The 2007-08 mortgage crisis serves as a stark reminder of the perils of unchecked greed and the complexities of our financial system. "The Big Short" presents a compelling narrative that illustrates the delicate interaction between individual actions and systemic failures. Whether viewed as a grand conspiracy or a predictable outcome of flaws, the crisis demonstrates that vigilance and reform in the financial industry are essential. As we consider the lessons from this tumultuous era, it is vital to recognize the potential for history to repeat itself. The financial landscape continues to change, and the risks of complex financial products remain significant. Gaining insight from the past allows us to better navigate the future and strive for a more stable and equitable financial system.

In the ever-evolving world of cryptocurrency, the allure of quick profits has drawn many into its depths. However, with the rise of digital currencies comes an equally troubling phenomenon: recovery scams. These scams prey on individuals who have already fallen victim to cryptocurrency theft, offering false hope and empty promises of recovering lost funds. This blog post aims to shed light on how these recovery scams operate, the tactics used by scammers, and how victims can protect themselves from falling into this second trap. Understanding Recovery Scams Recovery scams, often referred to as "scam-on-scam," involve fraudulent services that claim they can help victims recover their lost cryptocurrency. After a victim has been scammed, they may be desperate to regain their funds, making them prime targets for these unscrupulous operators. These so-called recovery services often employ fake lawyers, refund bots, and other deceptive tactics to extract more money from victims. The Mechanics of Recovery Scams Scammers typically reach out to victims through various channels, including social media, email, or even phone calls. They may present themselves as representatives of a legitimate recovery service or as legal experts specializing in cryptocurrency recovery. Their pitch often includes promises of a high success rate in recovering lost funds, which can be incredibly enticing for someone who has already suffered a financial loss. Fake Lawyers and Legal Services One of the most common tactics used in recovery scams is the impersonation of legal professionals. Scammers may create fake websites that mimic legitimate law firms, complete with testimonials and case studies. They often claim to have a network of contacts within law enforcement or regulatory agencies, which they use to convince victims of their legitimacy. Victims are then asked to pay upfront fees for legal services that never materialize. In many cases, these scammers will continue to ask for more money under various pretexts, such as court fees or administrative costs, leaving victims in a cycle of financial loss. Refund Bots and Automated Services Another prevalent method involves the use of automated systems or "refund bots." These bots claim to facilitate the recovery process by analyzing transactions and identifying potential avenues for recovery. Victims are often lured in by the promise of a quick and easy solution, only to find that the bot is nothing more than a sophisticated scam designed to extract personal information or additional fees. The Emotional Toll on Victims The impact of recovery scams extends beyond financial loss. Victims often experience feelings of shame, frustration, and hopelessness. After being scammed once, the idea of being scammed again can lead to a sense of despair. This emotional toll can make it even harder for victims to recognize the signs of a recovery scam, as they may be more willing to believe in the promises of recovery services out of desperation. Recognizing the Red Flags To protect themselves from falling victim to recovery scams, individuals should be aware of several red flags: Unsolicited Contact : Be wary of any unsolicited messages from individuals or companies claiming they can help recover lost funds. Upfront Fees : Legitimate recovery services typically do not require upfront payments. If a service asks for money before any work is done, it’s likely a scam. Lack of Transparency : Scammers often provide vague information about their services or refuse to share details about their methods. Pressure Tactics : If a service pressures you to act quickly or make a decision without proper research, it’s a significant warning sign. Protecting Yourself from Recovery Scams Awareness is the first step in protecting oneself from recovery scams. Here are some practical tips to help individuals safeguard their investments: Do Your Research : Before engaging with any recovery service, conduct thorough research. Look for reviews, testimonials, and any information that can verify their legitimacy. Consult Trusted Sources : If you’ve been scammed, consider reaching out to trusted friends or financial advisors for guidance before engaging with recovery services. Report Scams : If you encounter a recovery scam, report it to relevant authorities. This can help prevent others from falling victim to the same tactics. Educate Yourself : Stay informed about the latest scams and tactics used by fraudsters. Knowledge is a powerful tool in preventing future losses. Warning about cryptocurrency scams Conclusion Recovery scams represent a significant threat in the cryptocurrency landscape, exploiting the vulnerabilities of individuals who have already suffered financial loss. By understanding the tactics used by scammers and recognizing the signs of a recovery scam, individuals can better protect themselves from falling victim to these fraudulent schemes. Awareness, education, and vigilance are key in navigating the complex world of cryptocurrency and ensuring that one does not become a victim of a scam-on-scam scenario. Remember, if something seems too good to be true, it probably is. Stay informed, stay cautious, and safeguard your investments.